Regen BioPharma Series A Preferred Stock Begins Trading Under The Symbol RGBPP On The OTC PINK
SAN DIEGO, April 21, 2016 /PRNewswire/ --
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today that the company's Series A Preferred Stock began trading on the OTC PINK market (PINK: RGBPP). Regen BioPharma's shareholders now have a symbol and a market for the Series A Preferred shares they own.
Regen BioPharma Inc. is a biotechnology company that seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company is focused on rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. Currently the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia. The company has cleared an investigational new drug application (IND) with the U. S. Food and Drug Administration (FDA) and is preparing to enter Clinical Phase I in the treatment for aplastic anemia.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP). The company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company aims to rapidly advance these technologies through pre-clinical and Phase I/II clinical trials. Currently the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
David.koos@regenbiopharma.com
http://www.regenbiopharma.com
http://www.regenbiopharmainc.com
Twitter: Regen BioPharma News: https://twitter.com/RegenBioPharm
The Dorsee Company
Debra Dorsee
+1-858-229-6082
Debbie@thedorseecompany.com
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today that the company's Series A Preferred Stock began trading on the OTC PINK market (PINK: RGBPP). Regen BioPharma's shareholders now have a symbol and a market for the Series A Preferred shares they own.
Regen BioPharma Inc. is a biotechnology company that seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company is focused on rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. Currently the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia. The company has cleared an investigational new drug application (IND) with the U. S. Food and Drug Administration (FDA) and is preparing to enter Clinical Phase I in the treatment for aplastic anemia.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP). The company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company aims to rapidly advance these technologies through pre-clinical and Phase I/II clinical trials. Currently the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
David.koos@regenbiopharma.com
http://www.regenbiopharma.com
http://www.regenbiopharmainc.com
Twitter: Regen BioPharma News: https://twitter.com/RegenBioPharm
The Dorsee Company
Debra Dorsee
+1-858-229-6082
Debbie@thedorseecompany.com